Pharmacogenomic & Phase II Study of Gemcitabine and Pemetrexed in Non-Small-Cell Lung Cancer.
Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy and safety of chemotherapy given prior to having lung
cancer surgically removed. Patients with resectable non-small cell lung cancer will receive
gemcitabine and pemetrexed together for 4 times biweekly. Patients will be seen by a medical
oncologist prior to each cycle of chemotherapy given. The medical oncologist will review
patient's bloodwork and symptoms prior to approving next cycle of chemotherapy. All patients
will then be evaluated with scans to determine response to chemotherapy and to determine if
patient is a surgical candidate. These patients will then proceed to surgery to have the lung
cancer removed. Follow up visits include bloodwork, scans, and a visit with the medical
oncologist every three months for two years, then every six months for three years to monitor
for disease recurrence.
Phase:
Phase 2
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute
Collaborators:
Eli Lilly and Company National Cancer Institute (NCI)